Loading clinical trials...
Loading clinical trials...
A Prospective, Single-arm, Multicenter Phase II Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer
Conditions
Interventions
Iparomlimab and tuvonralimab
Locations
1
China
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China
Start Date
February 1, 2026
Primary Completion Date
December 31, 2028
Completion Date
December 31, 2029
Last Updated
March 3, 2026
NCT07536113
NCT07228832
NCT07286695
NCT06944548
NCT04627142
Lead Sponsor
Jiangsu Cancer Institute & Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions